By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) said Wednesday that China's medicines watchdog has approved the use of its drug Tagrisso as a first-line treatment for nonsmall cell lung cancer.
The U.K. pharmaceutical company said the medicine has been approved for patients with locally-advanced or metastatic cancer, and with tumors that showed certain genetic mutations, based on positive results from the phase 3 Flaura trial.
In the trial, Tagrisso used as a primary therapy was able to increase the amount of time patients lived without dying, or without having the disease progress, by a median of 18.9 months, versus 10.2 months for those being administered a standard alternative treatment.
Tagrisso was first approved in China in 2017 as a second-line treatment. With this approval, it will be able to be administered sooner after a patient is diagnosed.
Write to Carlo Martuscelli at firstname.lastname@example.org